Compare Stocks: SNY, MRK, NVS, and AZN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN Astrazeneca	$156.38 -0.5%	$174.16	$145.79 ▼ $212.71	$242.64B	0.26	3.96 million shs	3.70 million shs
MRK Merck & Co., Inc.	$135.78 +0.2%	$125.54	$77.58 ▼ $135.97	$335.14B	0.19	8.54 million shs	6.87 million shs
NVS Novartis	$151.02 -0.5%	$153.72	$121.57 ▼ $170.46	$287.90B	0.45	1.70 million shs	1.60 million shs
SNY Sanofi	$43.72 -0.1%	$43.33	$40.89 ▼ $52.68	$106.00B	0.35	3.44 million shs	2.72 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN Astrazeneca	0.00%	-3.04%	-7.51%	-13.90%	+0.32%
MRK Merck & Co., Inc.	0.00%	+5.57%	+6.35%	+21.93%	+64.24%
NVS Novartis	0.00%	-3.43%	-1.10%	+2.04%	+24.53%
SNY Sanofi	0.00%	+0.60%	-1.11%	+2.41%	-10.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN Astrazeneca	$156.38 -0.5%	$174.16	$145.79 ▼ $212.71	$242.64B	0.26	3.96 million shs	3.70 million shs
MRK Merck & Co., Inc.	$135.78 +0.2%	$125.54	$77.58 ▼ $135.97	$335.14B	0.19	8.54 million shs	6.87 million shs
NVS Novartis	$151.02 -0.5%	$153.72	$121.57 ▼ $170.46	$287.90B	0.45	1.70 million shs	1.60 million shs
SNY Sanofi	$43.72 -0.1%	$43.33	$40.89 ▼ $52.68	$106.00B	0.35	3.44 million shs	2.72 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN Astrazeneca	0.00%	-3.04%	-7.51%	-13.90%	+0.32%
MRK Merck & Co., Inc.	0.00%	+5.57%	+6.35%	+21.93%	+64.24%
NVS Novartis	0.00%	-3.43%	-1.10%	+2.04%	+24.53%
SNY Sanofi	0.00%	+0.60%	-1.11%	+2.41%	-10.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZN Astrazeneca	2.73	Moderate Buy	$211.00	34.93% Upside
MRK Merck & Co., Inc.	2.68	Moderate Buy	$135.50	-0.20% Downside
NVS Novartis	2.31	Hold	$141.20	-6.50% Downside
SNY Sanofi	2.40	Hold	$49.50	13.22% Upside

Current Analyst Ratings Breakdown

Latest SNY, MRK, NVS, and AZN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	MRK Merck & Co., Inc.	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$143.00
8/11/2026	MRK Merck & Co., Inc.	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
8/11/2026	MRK Merck & Co., Inc.	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$130.00 ➝ $145.00
8/5/2026	MRK Merck & Co., Inc.	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$145.00 ➝ $146.00
8/3/2026	SNY Sanofi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
7/29/2026	MRK Merck & Co., Inc.	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$140.00 ➝ $150.00
7/28/2026	AZN Astrazeneca	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
7/24/2026	NVS Novartis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B)
7/22/2026	NVS Novartis	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/13/2026	AZN Astrazeneca	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/13/2026	MRK Merck & Co., Inc.	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$135.00 ➝ $140.00

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZN Astrazeneca	$58.74B	4.13	$12.92 per share	12.10	$32.48 per share	4.81
MRK Merck & Co., Inc.	$65.01B	5.15	$11.42 per share	11.89	$17.02 per share	7.98
NVS Novartis	$54.53B	5.28	$10.75 per share	14.05	$21.98 per share	6.87
SNY Sanofi	$49.35B	2.15	$7.06 per share	6.19	$33.36 per share	1.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZN Astrazeneca	$10.23B	$6.69	23.38	13.74	1.35	17.02%	31.45%	13.20%	10/30/2026 (Estimated)
MRK Merck & Co., Inc.	$18.25B	$1.25	108.62	14.04	5.86	4.77%	16.73%	6.13%	10/29/2026 (Estimated)
NVS Novartis	$13.98B	$6.63	22.78	15.39	2.58	23.29%	38.56%	14.47%	10/27/2026 (Estimated)
SNY Sanofi	$8.84B	$1.91	22.89	8.39	1.09	8.66%	14.19%	7.95%	10/23/2026 (Estimated)

Latest SNY, MRK, NVS, and AZN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2026	Q2 2026	MRK Merck & Co., Inc.	-$0.26	-$0.13	+$0.13	-$0.54	$16.37 billion	$16.61 billion
7/30/2026	Q2 2026	SNY Sanofi	N/A	$2.41	N/A	$0.17	N/A	$13.36 billion
7/27/2026	Q2 2026	AZN Astrazeneca	$2.50	$2.63	+$0.13	$1.61	$15.44 billion	$15.38 billion
7/21/2026	Q2 2026	NVS Novartis	$2.17	$2.41	+$0.24	$1.71	$14.07 billion	$14.41 billion
6/30/2026	Q2 2026	NVS Novartis	N/A	$2.41	N/A	$1.71	N/A	$14.95 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZN Astrazeneca	$4.34	2.78%	+2.30%	64.87%	N/A
MRK Merck & Co., Inc.	$3.40	2.50%	+5.75%	272.00%	14 Years
NVS Novartis	$3.08	2.04%	+5.28%	46.46%	N/A
SNY Sanofi	$1.76	4.03%	+6.46%	92.15%	N/A

Latest SNY, MRK, NVS, and AZN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2026	MRK Merck & Co., Inc.	quarterly	$0.85	2.61%	9/15/2026	9/15/2026	10/7/2026
5/26/2026	MRK Merck & Co., Inc.	quarterly	$0.85	2.96%	6/15/2026	6/15/2026	7/8/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZN Astrazeneca	0.47	0.89	0.67
MRK Merck & Co., Inc.	1.22	1.32	1.06
NVS Novartis	0.89	0.86	0.67
SNY Sanofi	0.21	0.99	0.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZN Astrazeneca	20.35%
MRK Merck & Co., Inc.	76.07%
NVS Novartis	13.12%
SNY Sanofi	14.03%

Insider Ownership

Company	Insider Ownership
AZN Astrazeneca	N/A
MRK Merck & Co., Inc.	0.17%
NVS Novartis	0.01%
SNY Sanofi	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZN Astrazeneca	96,100	1.55 billion	N/A	N/A
MRK Merck & Co., Inc.	75,000	2.47 billion	2.46 billion	Optionable
NVS Novartis	75,267	1.91 billion	1.91 billion	Optionable
SNY Sanofi	74,846	2.42 billion	2.40 billion	Optionable

SNY, MRK, NVS, and AZN Headlines

Recent News About These Companies

The Manufacturers Life Insurance Company Lowers Position in Sanofi $SNY

August 12, 2026 | marketbeat.com

Dimensional Fund Advisors LP Trims Stock Holdings in Sanofi $SNY

August 12, 2026 | marketbeat.com

Why the Amlitelimab Setback Isn’t Enough to Sink Sanofi’s Multi-Billion Dollar Engine

August 10, 2026 | insidermonkey.com

Why the Amlitelimab Setback Isn’t Enough to Sink Sanofi’s Multi-Billion Dollar Engine

August 10, 2026 | finance.yahoo.com

Sanofi (NASDAQ:SNY) Rating Lowered to Hold at Wall Street Zen

August 9, 2026 | americanbankingnews.com

Sanofi (NASDAQ:SNY) Cut to "Hold" at Wall Street Zen

August 9, 2026 | marketbeat.com

Sanofi 2026 Q2 - Results - Earnings Call Presentation

August 7, 2026 | seekingalpha.com

Sanofi Says EU Expands MenQuadfi Approval

August 5, 2026 | finance.yahoo.com

Sanofi’s MenQuadfi approved in EU for infants against meningococcal disease

August 5, 2026 | msn.com

Why Investors Should Look at L3Harris, Cenovus, and Sanofi

August 5, 2026 | baystreet.ca

Press Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease

August 4, 2026 | manilatimes.netM

Quantinno Capital Management LP Buys 53,849 Shares of Sanofi $SNY

August 4, 2026 | marketbeat.com

Arrowstreet Capital Limited Partnership Sells 29,417 Shares of Sanofi $SNY

August 4, 2026 | marketbeat.com

Press Release: Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease

August 4, 2026 | globenewswire.com

Janus Henderson Group PLC Has $30.94 Million Holdings in Sanofi $SNY

August 3, 2026 | marketbeat.com

Sanofi (NASDAQ:SNY) Receives Consensus Recommendation of "Hold" from Analysts

August 3, 2026 | marketbeat.com

Bank of America Corp DE Buys 940,342 Shares of Sanofi $SNY

August 2, 2026 | marketbeat.com

Sanofi SA (SNY) (Q2 2026) Earnings Call Highlights: Strong Sales Growth and Upgraded Guidance ...

August 1, 2026 | sg.finance.yahoo.com

Sanofi (NASDAQ:SNY) Upgraded to "Buy" at Wall Street Zen

August 1, 2026 | marketbeat.com

Royal Bank of Canada Has $152.01 Million Stock Holdings in Sanofi $SNY

July 31, 2026 | marketbeat.com

Sanofi says weak decision-making hurt pipeline, promises more disciplined R&D

July 30, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNY, MRK, NVS, and AZN Company Descriptions

Astrazeneca NYSE:AZN

$156.38 -0.86 (-0.55%)

Closing price 08/14/2026 03:59 PM Eastern

Extended Trading

$156.24 -0.14 (-0.09%)

As of 08/14/2026 07:58 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Merck & Co., Inc. NYSE:MRK

$135.78 +0.23 (+0.17%)

Closing price 08/14/2026 03:59 PM Eastern

Extended Trading

$135.50 -0.28 (-0.21%)

As of 08/14/2026 07:56 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novartis NYSE:NVS

$151.02 -0.70 (-0.46%)

Closing price 08/14/2026 03:59 PM Eastern

Extended Trading

$150.93 -0.09 (-0.06%)

As of 08/14/2026 07:34 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Sanofi NASDAQ:SNY

$43.72 -0.06 (-0.14%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$43.80 +0.09 (+0.19%)

As of 08/14/2026 07:30 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SNY, MRK, NVS, and AZN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SNY, MRK, NVS, and AZN Earnings

Compare Dividends

Latest SNY, MRK, NVS, and AZN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SNY, MRK, NVS, and AZN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNY, MRK, NVS, and AZN Company Descriptions

Astrazeneca NYSE:AZN

Merck & Co., Inc. NYSE:MRK

Novartis NYSE:NVS

Sanofi NASDAQ:SNY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SNY, MRK, NVS, and AZN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SNY, MRK, NVS, and AZN Earnings

Compare Dividends

Latest SNY, MRK, NVS, and AZN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SNY, MRK, NVS, and AZN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNY, MRK, NVS, and AZN Company Descriptions

Astrazeneca NYSE:AZN

Merck & Co., Inc. NYSE:MRK

Novartis NYSE:NVS

Sanofi NASDAQ:SNY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools